Christine Alewine
American oncologist and biologist
Christine Alewine's AcademicInfluence.com Rankings
Download Badge
Medical Biology
Christine Alewine's Degrees
- Bachelors Biology University of California, Berkeley
- Doctorate Medicine Harvard University
- PhD Biomedical Sciences Stanford University
Similar Degrees You Can Earn
Why Is Christine Alewine Influential?
(Suggest an Edit or Addition)According to Wikipedia, Christine Campo Alewine is an American oncologist and biologist researching immunotoxin therapeutics in pancreatic cancer. She is an investigator at the National Cancer Institute. Education Campo completed a B.A. in chemistry and Asian studies at Dartmouth College. In college, she interned under chemist Karen Wetterhahn focusing on the environmental effects of toxic metals. It was in this lab that Alewine was introduced to MD–PhD programs and became interested in becoming a physician-scientist. She completed a postbaccalaureate program at the National Cancer Institute's laboratory of pathology from 1998 to 1999. Campo earned a M.D. and Ph.D. from the University of Maryland School of Medicine. Her dissertation in 2006 was titled, PDZ protein regulation of Kir 2.3. She completed internal medicine residency in the Osler Medical Training Program at Johns Hopkins Hospital followed by clinical fellowship in medical oncology at NCI.
Christine Alewine's Published Works
Published Works
- Mesothelin Immunotherapy for Cancer: Ready for Prime Time? (2016) (211)
- Advances in anticancer immunotoxin therapy. (2015) (151)
- Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors. (2017) (92)
- Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy (2019) (85)
- High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis (2015) (69)
- Efficacy of RG7787, a Next-Generation Mesothelin-Targeted Immunotoxin, against Triple-Negative Breast and Gastric Cancers (2014) (62)
- Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma (2015) (60)
- TIP-1 has PDZ scaffold antagonist activity. (2006) (47)
- New Life for Immunotoxin Cancer Therapy (2015) (38)
- Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient–Derived Xenografts and Mesothelin as a Biomarker of Tumor Response (2016) (29)
- Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma (2019) (28)
- Lin-7 targets the Kir 2.3 channel on the basolateral membrane via a L27 domain interaction with CASK. (2007) (23)
- Mesothelin-targeted immunotoxin RG7787 has synergistic anti-tumor activity when combined with taxanes (2016) (23)
- Molecular mediators of peritoneal metastasis in pancreatic cancer (2020) (23)
- Mesothelin Enhances Tumor Vascularity in Newly Forming Pancreatic Peritoneal Metastases (2019) (19)
- Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti–PD-1 antibody in patients with mesothelioma and mouse tumor models (2020) (19)
- Phase 1 study of the immunotoxin LMB‐100 in patients with mesothelioma and other solid tumors expressing mesothelin (2020) (18)
- Tofacitinib enhances delivery of antibody-based therapeutics to tumor cells through modulation of inflammatory cells. (2019) (15)
- A pilot study of immune checkpoint inhibition in combination with radiation therapy in patients with metastatic pancreatic cancer. (2017) (14)
- Mesothelin Expression in Advanced Gastroesophageal Cancer Represents a Novel Target for Immunotherapy (2016) (13)
- Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors (2020) (13)
- Inherited predisposition to malignant mesothelioma (MM) due to mutations in DNA repair genes. (2018) (9)
- Protein Synthesis Inhibition Activity of Mesothelin Targeting Immunotoxin LMB-100 Decreases Concentrations of Oncogenic Signaling Molecules and Secreted Growth Factors (2018) (9)
- Megakaryocytic Potentiating Factor and Mature Mesothelin Stimulate the Growth of a Lung Cancer Cell Line in the Peritoneal Cavity of Mice (2014) (8)
- Targeting the microenvironment of pancreatic cancer: overcoming treatment barriers and improving local immune responses (2016) (7)
- A pilot study of immune checkpoint inhibition (tremelimumab and/or MEDI4736) in combination with radiation therapy in patients with unresectable pancreatic cancer. (2016) (5)
- Caregiver Exclusion in the Age of COVID: Fighting Cancer With Half the Team. (2021) (5)
- Clinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma (2022) (4)
- A phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with nab-paclitaxel for patients with previously treated advanced pancreatic cancer. (2019) (3)
- Mesothelin expression in patients as a novel target in gastric cancer. (2014) (3)
- Phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with tofacitinib in persons with pancreatobiliary cancer or other mesothelin expressing solid tumors. (2021) (2)
- A phase II trial of the super-enhancer inhibitor Minnelide™ in advanced refractory adenosquamous carcinoma of the pancreas. (2022) (2)
- Furin is not required for processing of mesothelin precursor protein. (2021) (2)
- Phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with tofacitinib in patients with advanced pancreatobiliary cancer. (2021) (2)
- Abstract 2566: Combination of taxanes with mesothelin-targeted immunotoxin RG7787 induces synergistic killing of pancreatic cancer (2015) (2)
- Protein and Vesicle Trafficking , Cytoskeleton Lin-7 targets the Kir 2 . 3 channel on the basolateral membrane via a L 27 domain interaction with CASK (2007) (1)
- Novel Humanized Mesothelin-Expressing Genetically Engineered Mouse Models Underscore Challenges in Delivery of Complex Therapeutics to Pancreatic Cancers (2021) (1)
- Loss of ID3 in pancreatic cancer cells increases DNA damage without impairing MDC1 recruitment to the nuclear foci (2021) (1)
- Abstract PO-054: A phase II trial of the super-enhancer inhibitor Minnelide in advanced refractory adenosquamous carcinoma of the pancreas (ASCP) (2021) (1)
- Correlation of K-ras mutation with FDG uptake in colorectal cancer (2010) (1)
- Phase I study of mesothelin-targeted immunotoxin LMB-100 given as a long infusion with or without nab-paclitaxel. (2020) (1)
- Abstract PR07: Phase I/II study of mesothelin-targeted immunotoxin LMB-100 with nab-paclitaxel for patients with advanced pancreatic adenocarcinoma (2019) (1)
- Volume 22 Acknowledgments (2017) (0)
- Large Molecule Therapeutics Ef fi cacy of RG 7787 , a Next-Generation Mesothelin-Targeted Immunotoxin , against Triple-Negative Breast and Gastric Cancers (2014) (0)
- Abstract 268: Engineering of transgenic mice expressing human mesothelin for investigation of mesothelin-targeted therapeutics (2019) (0)
- Acknowledgment of Reviewers, 2017 (2017) (0)
- Abstract 93: Soluble mesothelin acts as a signaling molecule (2022) (0)
- Abstract 4505: Anti-tumor activity in pancreatic cancer of a low immunogenic and clinically optimized anti-mesothelin immunotoxin RG7787 (2014) (0)
- Thanks to Reviewers (2016) (0)
- Correlation of K-ras mutation with FDG uptake in lung cancer (2010) (0)
- P-133 Clinical responses in pancreaticobiliary cancer patients who received bintrafusp alfa (BA) or BA plus CXCR1/2 inhibitor (SX-682) plus CEA/MUC1-targted vaccine (CV301) (2022) (0)
- Abstract 3767: Characterization of the protumorigenic role of MSLN in peritoneal metastases in pancreatic cancer (2019) (0)
- Abstract C163: Understanding the mechanism for synergistic anti-tumor activity of a meosthelin-targeted immunotoxin and taxanes (2015) (0)
- Abstract 3964: Mesothelin targeting immunotoxin LMB-100 alters the profile of tumor-secreted proteins (2018) (0)
- Abstract A081: Phase I study of mesothelin-targeted immunotoxin LMB-100 given as a long infusion (2019) (0)
- Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment (2022) (0)
- Abstract B37: Mesothelin-targeted immunotoxin RG7787 (LMB-100) preferentially depletes secreted proteins and short-lived intracellular proteins to augment tumor cell killing by taxanes (2016) (0)
- Acknowledgment to reviewers—2017 (2017) (0)
- Abstract 1449: The molecular dissection of pro-tumorigenic activity of mesothelin in pancreatic cancer (2020) (0)
- Abstract 5440: Activity of mesothelin-targeted immunotoxin RG7787 against triple-negative breast cancer (2014) (0)
- Abstract 3103: The reduced immunogenicity anti-mesothelin immunotoxin RG7787 in combination with nab-paclitaxel has significant anti-tumor efficacy against primary mesothelioma cell lines and patient derived mesothelioma tumor xenografts (2016) (0)
- Abstract 104: Identification of the molecular components required for the protumorigenic effect of MSLN in pancreatic cancer (2018) (0)
- Molecular mediators of peritoneal metastasis in pancreatic cancer (2020) (0)
- Abstract 4342: Loss of MSLN impairs pancreatic cancer growth in the peritoneal cavity (2017) (0)
- Systemic immune changes accompany combination treatment with immunotoxin LMB‐100 and nab‐paclitaxel (2022) (0)
- Abstract 1280: Role of soluble mesothelin in peritoneal metastasis (2023) (0)
- Abstract C058: Remodeling the tumor microenvironment by targeting integrin alpha V beta 3 (αvβ3) expressing cells in pancreatic cancer (2022) (0)
- Abstract 3023: The antitumor activity of immunotoxins is enhanced by tofacitinib (2017) (0)
- BH3-Only Mimetics (2014) (0)
- Abstract B029: Deletion of mesothelin impairs intraperitoneal growth of pancreatic cancer (2018) (0)
This paper list is powered by the following services:
Other Resources About Christine Alewine
What Schools Are Affiliated With Christine Alewine?
Christine Alewine is affiliated with the following schools: